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ELSEVIER 
Chemical inactivation of recombinant 
vaccinia viruses and the effects on 
antigenicity and immunogenicity of 
recombinant simian immunodeficiency 
virus envelope glycoproteins 
Ellen G.J. Hulskotte*t, Marlinda E.M. Dings”?, Stephen G. Norley$ and 
Albert D.M.E. Osterhaus*$ 
The efficiency of paraformaldehyde (PFA) and binary ethylenimine (BEZ) in inacti- 
vating recombinant vaccinia virus (rW), present in baby hamster kidney cells 
expressing simian immunodefciency virus envelope glycoproteins (SIVEnv), was 
measured in a series of inactivation studies. Both compounds were shown to be 
effective in reducing rW titres. The use of standard 3-day titration assays proved to be 
inadequate to measure PFA inactivation, since upon prolonged incubation, residual 
rW infectivity was detected in cultures negative at 3 days. Different procedures using 
PFA or BEI were selected to assess their influence on the antigenicity and immuno- 
genic@ of rW expressed SIVEnv. Antigenicity, as defined by the ability to react with 
a panel of monoclonal antibodies recognizing major antigenic sites, and immuno- 
genicity, as defined by the ability to induce SIV envelope specific and virus neutralizing 
serum antibodies in ruts, proved to be preserved after either inactivation procedure. 
These data show that both protocols using PFA or BEI can be used successfully as part 
of the procedures to remove residual rW infectivity. 0 1997 Elsevier Science Ltd. 
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For the development of vaccines against human and 
animal lentiviruses, the use of viral subunits produced 
by recombinant DNA techniques is currently being 
evaluated. For this purpose, expression of viral proteins 
by recombinant vaccinia viruses (rVVs) is attractive for 
several reasons (for a review see Moss’). One of the 
conditions for the use of antigens produced in this way 
is the adequate removal of rVV infectivity from the 
final vaccine formulation. To this end, several chemical 
and physical procedures are available which should, 
however, not affect the antigenicity and immuno- 
genicity of the proteins expressed. 
Inactivation by formaldehyde is one of the 
procedures most frequently used to inactivate viruses 
in viral vaccines, although infections resulting from 
residual virus infectivity in formaldehyde inactivated 
vaccine formulation have been reported*. Formalde- 
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hyde reacts with amino, imino, amido, sulphydryl and 
hydroxy groups and with peptide linkages within 
proteins. One of its principal advantages is that, as a 
result of cross-linking, the gross three-dimensional 
architecture of proteins is conserved. In fact, the oligo- 
merit form of the envelope glycoprotein of human 
immunodeficiency virus (HIV) has been shown to be 
stabilized by formaldehyde treatment’. However, one 
drawback in the use of formaldehyde is the possible 
alteration or destruction of epitopes, which may result 
in an immunogen eliciting ineffective or even 
deleterious immune responses4,5. The antigenic struc- 
ture of several membrane proteins has been shown to 
be best preserved by paraformaldehyde (PFA), the 
polymeric form of formaldehyde’. In addition, antigen 
presenting cell function has been shown to be 
maintained after PFA fixation’-‘. 
Alternatively, one can hypothesize that compounds 
which inactivate viral infectivity without interaction 
with proteins would better preserve the antigenic struc- 
ture of a protein. One of the most widely used 
compounds in this respect is binary ethylenimine 
(BEI), an aziridine compound reacting with nucleic 
acids, which has been shown to efficiently inactivate 
several RNA and DNA viruses (for a review see 
Bahnemann’“). 
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In the present paper we evaluate the effects of both 
PFA and BEI treatment on the infectivity of rVVs in 
relation to their influence on the antigenicity and 
immunogenicity of the recombinant SIV-Env which 
they express. 
MATERIALS AND METHODS 
Recombinant vaccinia viruses 
The rVVs used in this study were: vSC65, a control 
rVV made by homologous recombination of the pSC65 
vector with vaccinia virus (WR strain)“; v8672-m and 
v8789-m, rVVs containing the cleavage site mutated 
8672-20 and 8789-11 SIV envelope gene, respectively’2. 
These SIV envelope genes were derived from 
SIVmac32H after different in vivo passages”. 
Inactivation experiments 
kcciniu virus infection. RVV was incubated in 
0.25 mg ml- ’ trypsin for 20 min at 37°C and vortexed 
regularly. Baby hamster kidney (BHK) cells were 
infected with the vaccinia virus preparation at a multi- 
plicity of infection of 1. After 24 h of incubation in 
complete medium (CM: Dulbecco’s Modified Eagles 
Medium, penicillin (100 IU ml-‘), streptomycin 
(100 G ml-‘), L-glutamine (2 mM), ,!&mercaptoethanol 
(2 x 1O-5 M)) supplemented with 5% FCS, cells were 
collected by centrifugation. 
PFA inactivation procedure. A PFA (Merck, 
Darmstadt, Germany) stock in PBS (pH 7.3) was 
freshly prepared before each experiment. To solubilize 
the PFA, 0.1% 4 N NaOH was added, followed by 
neutralization with an equal molar amount of 4 M 
HCI. Twenty-four hours after vaccinia virus infection, 
BHK cells were harvested by centrifugation and resus- 
pended in PBS at a concentration of 10’ ml -I. A 1 ml 
sample was taken to quantify vaccinia virus in the 
starting material. The remaining cell preparation was 
mixed with an equal volume of an appropriate PFA 
solution giving a final concentration of either 0.3% or 
1.5% or 7.5% (w/v) PFA. Samples were incubated at 
room temperature (RT) for various lengths of time as 
indicated. Thereafter, 10% (w/v) 1 M glycine (Merck) 
in PBS was added to stop the inactivation. Cells were 
centrifuged and resuspended in 0.2 M glycine in PBS. 
After 1 h incubation at RT, cells were collected by 
centrifugation, resuspended in CM at a concentration 
of 2 x 10’ cells ml-‘, and stored at -70°C until used for 
titration. 
BEI inactivation procedure. BEI was prepared 
freshly before each experiment according to a 
procedure described elsewhere”‘. Briefly, 2-bromo- 
ethylamine (BEA, Sigma, St. Louis, MO, USA) was 
dissolved in 0.175 N NaOH to a concentration of 0.1 M 
and incubated at 37°C for 30-60 min to allow cycliza- 
tion. The formation of BE1 was verified by measuring 
the pH which dropped from 12.5 to 8.5. As initial 
studies performed with 1.5 mM BEI in DMEM 
containing 1 mM ethylene-diamine-tetra-acetic acid 
(EDTA, Merck), 2 mM phenyl-methyl-sulfonyl-fluoride 
(PMSF, Sigma), 2 pg ml-’ leupeptin (Sigma) and 2% 
FCS did not allow consistent vaccinia virus inactivation. 
further experiments were conducted in PBS (pH 7.6) 
containing 1 mM EDTA, 2 mM PMSF and 2 ,ug ml-’ 
leupeptin at varying BE1 concentrations and incubation 
periods. Twenty-four hours after vaccinia virus infec- 
tion, BHK cells were harvested by centrifugation and 
resuspended at 10’ ml-’ in PBS (pH 7.6). A 1 ml 
sample was taken to quantify vaccinia virus in the 
starting material. The remaining cells were mixed with 
0.1 M BEI at a final concentration of either 1.5 mM or 
7.5 mM. To control for decline in vaccinia virus infec- 
tivity in time, a control sample without BEI was run in 
parallel. After incubation at 37°C for various lengths of 
time as indicated, virus inactivation was stopped by the 
addition of 1 M sodium-thiosulphate at 10% of the 
volume of the BE1 solution used. Samples were stored 
at -70°C until used for titration. 
Infectivi& assessment by 3-day plaque titration. Trypsin 
(Gibco BRL, Life Technologies, Paisley, Scotland,) was 
added to 100 ~11 of each sample at 0.25 mg ml- and 
incubated for 20 min at 37°C. Ten-fold serial dilutions 
in CM were made and 100 pl aliquots were added in 
quadruplicate to rabbit kidney ceils (RK13 cells) 
seeded in 24-well plates (Costar, Cambridge, USA). In 
addition, 100 ~1 aliquots of each undiluted sample were 
added in quadruplicate to RK13 cells. Samples were 
incubated on a rocker for 90 min at RT, diluted with 
1 ml of CM containing 2.5% FCS and further 
incubated at 37”C/5% CO2 for 3 days. To count 
plaques, cells were stained with 0.8% crystal violet in 
50% ethanol/5% formalin. Virus titre was defined as 
the number of plaque forming units per millilitre 
(pfu ml-‘) containing 10’ vaccinia virus-infected BHK 
cells. The detection threshold was 2.5 pfu ml ‘. 
Long-term (21 day) infectivity assessment. Samples 
were prepared as described above. 200 111 of undiluted 
or 500 ~1 of ten-fold serial diluted trypsinized sample 
was added to RK13 cells seeded in 25 cm2 flasks and 
incubated on a rocker for 90 min at RT. Subsequently, 
4 ml of CM containing 2.5% FCS was added and the 
flasks were further incubated at 37”C/5% CO2 for 
3 weeks. Cultures were split 1 in 5 twice a week. 
Production of recombinant SWEnv and preparation 
of iscoms 
The production of SIV-Env and their incorporation 
into iscoms was performed as described previously”. 
Briefly, BHK cells were infected with either rVV 
v8672-m or v8789-ml*. Subsequently, cells were 
collected and treated with either 1.5% PFA in PBS for 
30 min at RT or with 1.5 mM BE1 in DMEM 
containing 1 mM EDTA, 2 mM PMSF and 2 pg ml-’ 
leupeptin and 2% FCS for 24 h at 37°C. The envelope 
proteins were solubilized from the membrane by 
incubation in 4% Rosenbuch-Tenside (RBT, n-octyl- 
polyoxy-ethylene; Bachem, Bubendorf, Switzerland), 
enriched by lentil-lectin chromatography and incor- 
porated into iscoms by the dialysis method. 
Immunization of rats 
Two groups of four female rats (RIV:tox) were 
immunized intramuscularly at weeks 0 and 4 with 3 pg 
of 8789-m SIV-Env incorporated into iscoms. The Env 
was solubilized from rVV-infected BHK cells treated 
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with either 1.5% PFA for 30 min at RT or 1.5 mM BEI 
for 24 h at 37°C. Serum samples were collected 0, 2, 4, 
5, 6, 8. and 14 weeks after the first immunization. 
Binding of monoclonal antibodies (Moabs) to different 
SWEnv preparations 
The reactivity of SIV-Env 8672-m and 8789-m, 
derived from either non-inactivated or PFA or BE1 
inactivated rVV-infected BHK cells, with a panel of 
Moahs (kindly provided by Dr K. Kent, in ,part through 
MRC) was tested by ELISA as described . The panel 
consisted of 14 murine Moabs which could be divided 
into six competition groups’.7,‘4 located at the surface 
and transmembrane part of the SW-Env (see also 
Figure 3). The Moabs of competition group 1 recog- 
nize conformation dependent epitopes. They all cross- 
compete but differ in their ability to react with 
different strains of SIV, to compete with Moabs recog- 
nizing the V3 region of SIV, and to inhibit CD4-gp120 
binding”-“. Further mapping has shown that the 
conformation dependent epitope recognized by KK9 
involves the V3 and the V4 domain, that the epitope of 
KK5 involves V4 but not V3, and that KK56 recognizes 
a conformation dependent epitope involving the CD4 
binding site’“. 
Detection of SWEnv specific antibodies 
Envelope specific antibodies were detected by a 
whole SIV ELISA as described12. Briefly, concanavalin- 
A-coated 96-well plates were incubated with a 
SIV-infected C8166 cell lysate. After overnight incuba- 
tion, wells were blocked and incubated with two-fold 
dilutions of rat serum. Bound antibody was detected by 
rabbit-anti-rat Ig-horseradish peroxidase (HRPO) 
antibodies (DAKO, Gostrup, Denmark). The substrate 
reaction was carried out with 3,3’,5,5’-tetramethyl- 
benzidine. Endpoint titres were calculated using as 
cut-off value twice the 0D4s,, given by parallel dilutions 
of the pre-immune serum. Comparison of titres 
between the immunization groups was conducted using 
a one-way analysis of variance (Anova; Minitab Inc., 
State College, USA). Titres were considered signifi- 
cantly different if P ~0.05. 
Inhibition of a virus neutralizing antibody (KK56) 
To demonstrate the presence of antibodies capable 
of inhibiting the virus neutralizing (VN) antibody 
KK56’“. an inhibition ELISA was used as described ’
with minor modifications. Briefly, concanavalin- 
A-coated 96-well plates were incubated with 100 ~1 of 
SIV-infected C8166 cell lysate. Two-fold dilutions of 
rat serum in 100 ill were added for 1 h at RT. Subse- 
quently, 50 ~1 was replaced with 50 ~1 of KK56 diluted 
to give an absorbance at OD,,,, of 70% of the 
maximum absorbance in an indirect SIV-ELISA. Plates 
were incubated with a biotin-conjugated goat-anti- 
mouse IgG antibody preparation (Amersham), and 
subsequently with HRPO conjugated streptavidine 
(Amersham). Inhibition titres were defined as the 
dilution of rat serum inhibiting 50% of the absorbance 
measured without competing antibody. The difference 
in titre between the two immunization groups was 
evaluated through a Student’s t-test. Differences of 
P < 0.05 were considered significant. 
SIV neutralization assay 
The SIV neutralization assay was performed with 
SIVmac32H as describedIg. Briefly, 10 ~1 of serial 
dilutions of heat-inactivated sera were incubated in 
four replicate wells with 10 ~1 of SIVmac32H at 10 
infectious particles per 10 ~1. After 30 min incubation 
at 37°C 2 x 10’ C8166 cells in 200 ~1 were added to 
each well. Cells were incubated for 7 days at 37°C 
transferred to poly-L-lysine flat-bottom microtiter 
plates, fixed in methanol, and examined for SIV infec- 
tion by a SIV specific immunoperoxidase assay. The 
number of negative wells was used to determine the 
neutralizing dose 50% endpoint (ND50) for that serum 
by the method of Spearmann-Karber. The difference 
in titre between the two immunization groups was 
evaluated through a Student’s t-test. Differences of 
P < 0.05 were considered significant. 
RESULTS 
Inactivation of vaccinia viruses in BHK cells 
(i) PFA inactivation. Three concentrations of PFA, 
0.3%, 1.5% and 7.5%, were tested for their ability to 
inactivate rVVs present in BHK cells. The kinetics of 
inactivation were determined by assessing residual 
infectivity in a 3-day plaque titration assay (Figure IA). 
Complete inactivation of rVVs appeared to be 
achieved with all three concentrations of PFA, within 
about 0.5, 8 and 50 min, respectively. The rate of 
inactivation was found to increase with the 
concentration of PFA (Figure IB). However, when 
time (minutes) 
Figure 1 Inactivation of rVVs present in BHK cells with 0.3%, 
1.5% and 7.5% PFA at RT as measured by assessing residual 
infectivity in a 3-day plaque titration assay. (A) Kinetics of inactiva- 
tion of vaccinia virus. (8) Extrapolation of the decrease of vaccinia 
virus infectivity in time. The data shown are representative for at 
least two independent experiments. Inactivation curves were 
generated using control rVV vSC65, expressing no recombjnant 
protein, or rVVs v8672-m or v8789-m expressing SIV-Env 
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cultures were maintained for prolonged periods, 
residual infectivity could be detected in all PFA treated 
samples within 3 weeks (see Table I). In none of the 
concentrations tested did the effective inactivation with 
PFA therefore exceed 10h pfu ml- ’ rVV-infected BHK 
cells. As PFA interacts with proteins, we subsequently 
tested the effects of different concentrations and 
incubation times of PFA inactivation on the yields of 
SIV-Env obtained from rVV-infected cell preparations 
by detergent solubilization. As shown in Table I, the 
recovery of SIV-Env proved to be inversely related to 
PFA concentration and duration of treatment. 
(ii) BEZ inactivation. In pilot experiments, inactiva- 
tion of vaccinia virus with BE1 was shown to be more 
efficient at 37°C compared to 20°C (data not shown). 
Therefore, two concentrations of BEI, 1.5 mM and 
7.5 mM, were tested for their ability to inactivate 
vaccinia virus at 37°C using different incubation 
periods (Figure 2A). Complete inactivation of rVVs 
was found with both concentrations of BEI, within 8 
and 24 h, respectively. The rate of inactivation was 
found to increase with the concentration of BE1 (Figure 
2B). In contrast to inactivation with PFA, inactivation 
with BE1 did not result in recovery of residual infec- 
tivity upon prolonged incubation (Table 1). 
Antigenicity of rW expressed SIV-Env after PFA and 
BEI treatment 
On the basis of their inactivation kinetics and for 
practical reasons, the following procedures using PFA 
and BE1 were selected to evaluate their effects on 
antigenicity and immunogenicity, respectively: 1.5% 
PFA for 30 min at RT; 1.5 mM BE1 for 24 h at 37°C. 
The effect of PFA and BE1 inactivation on the antige- 
nicity of rVV v8672-m and rVV v8789-m expressed 
SIV-Env was assessed by evaluating their reactivity 
with a panel of 14 SIV envelo e s 
L.,P 
ecific Moabs recog- 
nizing major antigenic sites (Figwe 3). These 
Moabs included the virus neutralizing Moabs KKlO 
and KK54 recognizing linear epitopes and KK5, KK9, 
and KK56 recognizing different conformation 
dependent epitopes’. -I’. With all the Moabs tested, the 
reactivity of PFA or BE1 treated SIV-Env was essen- 
tially the same as that of SIV-Env recovered without 
prior use of an inactivation method. 
Immunogenicity of RW expressed SIV-Env after PFA 
and BE1 treatment 
To investigate the immunogenicity of SIV-Env, rats 
were immunized with rVV v8789-m expressed SIV-Env 
incorporated into iscoms after inactivation either with 
PFA or BEI. The overall levels and kinetics of SIV 
specific antibody titres were virtually identical in rats 
immunized with either PFA or BE1 treated SIV-Env 
(Figure 4A). In addition, no significant difference was 
found in titres of serum antibodies capable of 
inhibiting the VN antibody KK56, as well as total VN 
serum antibodies (Figure 4B and C). Similar results 
were obtained using rVV v8672-m expressed SIV-Env 
incorporated into iscoms for immunization (data not 
shown). 
DISCUSSION 
In the present study, we have shown that both PFA 
and BE1 inactivate vaccinia virus in a dose- and time- 
dependent fashion. However, in samples which scored 
virus negative in a standard 3-day plaque titration 
assay, residual infectivity could be detected in PFA but 
not BE1 treated samples when cultures were 
maintained for up to 3 weeks. Treatment of 
rVV-infected BHK cells with 1.5% PFA for 30 min at 
RT or 1.5 mM BE1 for 24 h at 37°C preserved the 
reactivity of rVV expressed SIV-Env with a panel of 14 
Moabs recognizing the major antigenic sites on the SIV 
envelope glycoprotein. The immunogenicity of 
SIV-Env, as defined by SIV specific serum antibody 
titres, inhibition to a VN monoclonal antibody and 
total VN antibody titre against SIVmac32H, proved to 
be comparable using either inactivation method. 
Formaldehyde is widely used to inactivate viral 
vaccines”. However, accidents due to residual virus 
infectivity in formaldehyde inactivated vaccine prepara- 
tions have been reported’. Residual infectivity has been 
attributed to non-linearity of the inactivation curves, 
reversion of the process of formaldehyde mediated 
inactivation, slow adsorbtion of formaldehyde treated 
virus to cells, and retarded penetration of the virus into 
Table 1 Measurement of residual vaccinia virus infectivity using a 3- or 21-day titration assay and recovery of SW-Env from differently 
inactivated rVV infected BHK cells 
Decrease in infectivity 
(log pfu ml-‘) 
Compound Incubation period (min) 3 days” 21 days! 
7.5% PFA 0.5 >8 6 
1.5 >8 nd 
3 >8 6 
1.5% PFA 15 >8 5 
30 >8 6 
0.3% PFA 60 >8 3 
180 >8 nd 
360 >8 6 
1.5 mM BEI 24h >8 >8 
“Decrease in vaccinia virus infectivity as determined in a standard 3-day plaque titration assay 
bDecrease in vaccinia virus infectivity as determined by maintenance of cultures for 21 days 
“Yield of SIV-Env obtained from rVV v8789-m infected BHK cell preparations by solubilization with 4% RBT 
nd: not done 
Yield” (Llg SW-Env ml- ‘) 
nd 
0.7 
0.4 
3.1 
2.8 
nd 
4.2 
2.4 
nd 
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the ~ell’~.““~. In the present study, using PFA for inacti- 
vation, residual vaccinia virus infectivity was found in 
cultures that had scored virus negative in a standard 
3-day plaque titration assay, after additional culturing 
for up to 3 weeks. Apparently, the conditions used did 
not result in an inactivation of more than six logs. In 
contrast, the calculated inactivation which would result 
from a hypothetical inactivation curve based on extrap- 
olation of the data obtained in the 3-day plaque titra- 
tion assay would have been more than lo”’ pfu ml ’ 
( 1.5% PFA for 30 min at RT). It therefore seems most 
likely that the late recovery of infectivity is due to a 
delay in regaining virus infectivity rather than to an 
asymptotic nature of the inactivation curve. However, 
more detailed experiments are needed to elucidate the 
exact underlying mechanism, and whether for instance 
the relapse in infectivity could be overcome by 
changing the conditions used, such as even longer 
incubation periods, higher concentrations of PFA, or 
different incubation temperatures. Inactivation of 
vaccinia virus in this study may also have been compli- 
cated by the fact that inactivation is carried out with 
intact vaccinia virus-infected cells and not with cell fret 
virus. 
From these data it has become clear that inactiva- 
tion based solely on PFA treatment may not be suffi- 
cient. In the procedure to make the experimental 
SIV-Env vaccine preparation used for immunization, 
additional steps to isolate and purify the protein may 
have contributed to inactivating or removing vaccinia 
virus. These steps include detergent extraction. which 
time (hours) 
Figure 2 Inactivation f rVVs present in BHK cells with 1.5 mM 
and 7.5 mM BEI at 37°C as measured by assessing residual infec- 
tivity in a 3-day plaque titration assay. (A) Kinetics of inactivation of 
vaccinia virus. (B) Extrapolation of the decrease of vaccinia virus 
infectivity in time. The data shown are representative for at least 
two independent experiments. Inactivation curves were generated 
using control rVV vSC65, expressing no recombinant protein, or 
rVVs v8672-m or v8789-m expressing SIV-Env 
reduces infectivity with at least six logs (data not 
shown), lentil-lectin affinity chromatography and 
iscom preparation including dialysis and sucrose 
gradient centrifugation, which in general give 
additional reductions in virus titrc of about three to 
four logs each”. We could never demonstrate residual 
infectivity in iscom preparations produced in this way: 
neither in vitro (data not shown) nor in V~IJO upon 
immunization of rats (present study and Hulskotte et 
~1.“) or monkeys”’ with recombinant SIV-Env derived 
from rVV-infected BHK cells originally containing 
about 0.3 to 1 x lo” pfu per immunization dose, 
respectively. 
In several studies BEI has been shown to efficiently 
inactivate RNA and DNA viruses”‘. Inactivation was 
found to be linear in time with inactivation rates 
ranging from 0.5 to 4.1 log h ’ using 1 mM BE1 at 
37°C”‘. In our study, the calculated inactivation rate of 
vaccinia virus with I.5 mM BEI at 37°C was on average 
1.3122 1 A. 8672-m b -I 
4374 
1458 
486 
162 
v 
_. 13122 /- 6. 8789-m -I 
162 
54 
18 
~~~~ 5 9 56 822 10135254 3 46 7 2014 
Figure 3 Binding of 14 Moabs to rVV v8672-m (A) and rVV 
v8789-m (B) expressed SIV envelope glycoproteins recovered 
either without prior use of an inactivation procedure for vaccinia 
virus or after inactivation with 1.5% PFA for 30 min at RT or with 
1.5 mM BEI for 24 h at 37°C. Competition groups are defined by 
Kent et a/.‘3~‘4~‘6. The Moabs of competition group I recognize 
conformation dependent epitopes. They all cross-compete but 
differ in their ability to react with different strains of SIV, to 
compete with Moabs recognizing the V3 region of SIV and to 
inhibit CD4-gp120 binding15 17. SU, surface glycoprotein; TM, 
transmembrane glycoprotein; Aa, amino acid numbers BK28 SIV 
envelope protein; conf., conformation dependent epitope; na, not 
applicable, 8672-m envelope glycoprotein is hardly recognized by 
Moabs of competition group 1”. Bars represent the dilution of 
monoclonal antibody giving 50% of the maximum OD450 using 
that monoclonal antibody. n : 8672-m; 
8672-m BEI; >: 8789-m; 0: 8789-m PFA; n : 8789-m BEI. Binding 
of Moabs to untreated 8672-m and 8789-m envelope glycoproteins 
has been published before in Hulskotte et a/.‘* 
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Figure 4 Induction of SW-Env specific antibodies in rats 
immunized with rVV v8789-m expressed SIV-Env incorporated into 
iscoms after inactivation either with PFA or BEI. Data on SIV-Env 
specific antibody induction after PFA treatment h&e been 
published before in Hulskotte et al.‘*. (A) Mean SIV antibody titre 
from four rats immunized with the same SIV-Env preparation. 
Weeks of immunization are indicated by arrows. (8) Inhibition of 
binding of the virus neutralizing monoclonal antibody KK56 by 
monkey sera. (C) SIV virus neutralizing antibody response before 
immunization (Week 0) and at peak level of antibody response 
(Week 6 post-primary immunization). Mean titres from four rats are 
shown with the standard error of the means presented as a 
horizontal line 
about 0.4 log h ‘. A more detailed analysis of the 
inactivation curves will be needed to precisely deter- 
mine the inactivation rate at all stages. 
There are several indications that the SIV envelope 
protein did not dramatically change its conformation 
by either the PFA or the BEI treatment. First, the 
recognition of the envelope protein by a group of VN 
antibodies specific for conformational epitopes was 
preserved. Second, VN antibodies were induced by 
immunization with PFA or BE1 treated SIV-Env. As 
large parts of VN antibodies present in sera from 
SIV-infected monkeys” and HIV-infected humansZx~‘” 
are conformation dependent, this finding may indicate 
a rather native conformation of the SIV-Env studied. 
Our results with PFA treated SIV-Env arc also in 
agreement with the findings of Sattentau et af.j” 
showing the conservation of four neutralizing epitopcs 
on HIV-1 gp120 after formaldehyde treatment. 
Overall, the results generated in the present studies 
are encouraging for the proposed inclusion of rccombi- 
nant proteins expressed by rVVs in experimental viral 
vaccines, since they show that antigenicity and 
immunogenicity of the highly glycosylated SIV-Env 
glycoprotein are preserved. Treatment of rVV infected 
cells with 1.5 mM BE1 at 37°C resulted in complete 
inactivation. PFA treatment was shown to give a 
delayed appearance of residual vaccinia virus infectivity 
after prolonged culture, and therefore additional 
procedures are needed if this compound is to be used 
in the preparation of vaccines for human USC. 
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